Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae - Wikidata - wikimedia - TriplyDB

Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae

Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae

http://www.wikidata.org/entity/Q34483491

about

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing Carbapenemases Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC -Lactamases Clinical management of infections caused by multidrug-resistant Enterobacteriaceae New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4 Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.The enzymes of β-lactam biosynthesis.Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance.In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections.Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study.Enhancing the utility of existing antibiotics by targeting bacterial behaviour?Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases Experimental model for treatment of extended spectrum betalactamase producing-Klebsiella pneumoniae.Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.Challenges and opportunities in developing novel drugs for TB.Current strategies for the treatment of complicated intraabdominal infections.Confronting carbapenemase-producing Klebsiella pneumoniae.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.β-lactam/β-lactamase inhibitor combinations: from then to now.Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options.Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying blaKPC Collected in U.S. Hospitals from 2012 to 2015.Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.

P2860

Q24601746-7E9995EA-48B0-4058-BBCD-15B4B6973CEA Q26747580-2FBFE9C6-2F97-49C5-91EB-2DC9FDA73AB3 Q27676626-EAD4AF92-A64D-4C99-BB70-6714E5C23E64 Q28246841-67A2BC38-6F1E-44BC-9B34-71555E8346B3 Q33622976-ADAB07BA-F0B6-4A50-93EA-445A2F3FF215 Q33631108-AB4315CC-79E1-4943-B991-5A6D50B71A6E Q34058217-0EBB848B-5C4D-44ED-BD6C-53B4C18484E5 Q34310470-2D00B4AF-0214-4A77-8B8B-1A38ED1E1A83 Q34325573-9E23FCD5-E493-47A4-BD5A-B9BD82B56D89 Q34402134-E023B372-51F2-4363-AECD-A2964E34A26B Q34426513-D0FCDB09-1A0C-4C64-A23A-76FCA36FA629 Q34596516-1F57B4D3-1A47-4ED0-8226-F7CAAD8605B4 Q35106776-A4ED0257-1E04-48D3-BEBC-F239942D03E3 Q35168955-A6544A2D-517E-4108-A41F-45F633DB83F4 Q35764780-0E699492-6CB9-4E52-9240-2BEBE65E3712 Q35853204-7490E24B-86FB-4060-9626-B89222F1A005 Q36122731-619C88A3-40FC-4CE0-9B87-45E8E7B68A83 Q36357629-A6AEA8E0-22FC-43D4-B435-5D27E51E806B Q36364859-9CCA0F37-4DC4-43F5-A573-91377E7B8FC6 Q36396244-3FAA1682-68C5-46DC-BE4F-3C1F9FE27964 Q36439179-AE30E864-2DFE-464E-AD90-4F1C634F3F77 Q36571851-6CDF8D77-7EEC-43BE-BE5C-3AB5E59F5399 Q37146405-84C904F0-AA7C-4205-AE68-ACA6F4583179 Q37894694-52330EF8-7CAD-4896-9A60-D54376659B46 Q37924294-866843C1-C8A3-4667-9292-3CBFC17615B9 Q38123247-B645CDB4-6552-4D57-9EC3-FE32693A64CA Q38135903-0A6D8B27-0943-4D64-8A1C-F579FD86BBEE Q38262205-F0546D5C-2A1D-4D3A-9321-A69988542756 Q38264182-91824321-F59B-453C-B37D-D5E972C6CBE3 Q38325959-52EB8A19-9093-480F-AA21-38F1F04CE273 Q38392082-6F116121-7FB9-45C1-9C7D-D8AD3E520995 Q38543002-6846ED0E-E570-4ACF-B082-3B3681A8357D Q38595451-BD03A10B-A66A-4A12-9319-EC435AF9D3D8 Q38783043-71ECC6E8-95E4-4649-A2DC-2F3078B6C3E1 Q38797485-73099F6B-C033-43A2-9A74-17AA83147519 Q38944862-08108B18-D6AA-42ED-B8AC-4CEFCAAF8C25 Q38975480-D45642E2-39DE-4F77-BD8F-C55D86340D5F Q40392503-C2486D9B-C390-4553-BC75-9C45FCAEACD7 Q41077573-C39FFEDF-6EE1-43AD-B5EC-23F48D8A8301 Q41240109-94B5986D-22DF-4A4A-9F0B-327BA792B44A

P2860

Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae

http://www.wikidata.org/entity/Q34483491

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@ast

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@en

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@nl

type

label

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@ast

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@en

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@nl

prefLabel

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@ast

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@en

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@nl

P1433

Q34483491-F857E533-51A0-4C7A-BDC1-734286D80CD6

P1476

Q34483491-6200E48F-2594-4214-98F9-66F5D0436809

P2093

Q34483491-0BCFE433-A700-4010-B1A8-BC0DAAEABFD3

Q34483491-37F8E04E-8D0D-4A0B-9C36-613025C88ECA

Q34483491-C404C9BA-E312-4104-BEA3-4753A0E9BFD9

Q34483491-D5B0E7FB-6B45-44FC-BF7C-66D6DFDC1EBA

P2860

Q34483491-0875EC1B-D48E-4659-91FB-7EFE72B92C72

Q34483491-10111F8F-B02B-40A3-A795-84073C9E621A

Q34483491-1762F807-5C15-49D7-973A-C04B95099DB9

Q34483491-218FC881-9519-4E3F-90C6-DBC07BB2861E

Q34483491-5535A49A-4B6B-4FDD-BA2C-64A420C40FBD

Q34483491-62E88C7F-2FBA-4C01-BC71-135576ABB348

Q34483491-66EDA402-E27B-47B3-98C2-B80018B01DA6

Q34483491-6EAE8206-997A-487D-AA8F-30D2DC7ABB04

Q34483491-6EE418D0-9466-4594-91AE-5A17CD4EA3DE

Q34483491-7E36044F-BB8D-4485-826E-1113EFFED821

P304

Q34483491-E0636BFE-5124-4B65-95FC-11192AB66BBF

P31

Q34483491-65DA85F4-EBD4-4D0F-9ADB-FCD92FB7D7C2

P356

Q34483491-E8197CE5-2C70-40BD-B92D-E097359410E9

P407

Q34483491-C6C39CA8-ED22-4C83-8D31-E9C926F230B6

P433

Q34483491-0DD18A9B-0A2E-4BA9-8FBC-0B5D37D44FAB

P478

Q34483491-471CCA9F-6C0A-49E2-86A8-AAA96E8A3562

P50

Q34483491-21013CCF-BF43-490A-B12C-BCBE917BD755

Q34483491-F0A447C1-31C5-4FBA-AB01-19889CC2CE1C

P577

Q34483491-EE68ED5E-0E82-4BBF-AF2F-BD20373A7F02

P5875

Q34483491-34C773F9-5C3E-4CE9-B048-46BB2B67D3FE

P698

Q34483491-C07C6EA1-9FB9-4334-B568-5114B2867FAF

P921

Q34483491-1C82C8E6-5D12-49CF-BB78-E151F1B6CB5E

P932

Q34483491-95BEB576-C51E-440C-A94E-6B2CC9E35502

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Evaluation of ceftazidime and ...... roducing Klebsiella pneumoniae

@en

P2093

Andrea Endimiani

http://www.w3.org/2001/XMLSchema#string

Kristine M Hujer

http://www.w3.org/2001/XMLSchema#string

Mark E Pulse

http://www.w3.org/2001/XMLSchema#string

William J Weiss

http://www.w3.org/2001/XMLSchema#string

P2860

Three decades of beta-lactamase inhibitors

Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae

In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.

Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study.

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.

Hospital-acquired infections due to gram-negative bacteria.

Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.

Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility.

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.

P304

82-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01198-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Robert A Bonomo

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47644788

http://www.w3.org/2001/XMLSchema#string

P698

21041503

http://www.w3.org/2001/XMLSchema#string

P921

Klebsiella pneumoniae

P932

3019638

http://www.w3.org/2001/XMLSchema#string